Non-steroidal mineralocorticoid receptor antagonists in heart failure

Non-steroidal mineralocorticoid receptor antagonists in heart failure

Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews cardiology 2023-10, Vol.20 (10), p.645-646
Hauptverfasser: Filippatos, Gerasimos, Farmakis, Dimitrios
Format: Artikel
Sprache:eng
Schlagworte:
692/699/75/230
692/700/565/1436
Cardiac Imaging
Cardiac Surgery
Cardiology
Clinical Outlook
Diabetes
Ejection fraction
Enzymes
Heart failure
Hospitalization
Hyperkalemia
Kidney diseases
Medicine
Medicine & Public Health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 646
container_issue 10
container_start_page 645
container_title Nature reviews cardiology
container_volume 20
creator Filippatos, Gerasimos
Farmakis, Dimitrios
description Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safety and promising early results in patients with heart failure.
doi_str_mv 10.1038/s41569-023-00922-x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2858986648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2858986648</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-a6a60c6d1d0cca536961ae7a9a4986b054ad34dff4dfab40df57b6c060f4713</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhhdRsFb_gKcFL15WJ5-7e5RSP6DoQe9hms3WlG1SkyzUf2-0ouDBw5AhPO_L8BTFOYErAqy5jpwI2VZAWQXQUlrtDooJqUVbCSBw-LMDPS5OYlwDSF4LNinmj95VMZngbYdDubHOBBy89iFZnf_KYLTZJh9KdAlX3tmYYmld-WowpLJHO4zBnBZHPQ7RnH2_0-L5dv4yu68WT3cPs5tFpZmgqUKJErTsSAdao2CylQRNjS3ytpFLEBw7xru-z4NLDl0v6qXUIKHnNWHT4nLfug3-bTQxqY2N2gwDOuPHqGgjmtwjeZPRiz_o2o_B5dsyJTkHmoVkiu4pHXyMwfRqG-wGw7sioD69qr1Xlb2qL69ql0NsH4oZdisTfqv_SX0Av7t8fA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864402175</pqid></control><display><type>article</type><title>Non-steroidal mineralocorticoid receptor antagonists in heart failure</title><source>SpringerLink Journals</source><creator>Filippatos, Gerasimos ; Farmakis, Dimitrios</creator><creatorcontrib>Filippatos, Gerasimos ; Farmakis, Dimitrios</creatorcontrib><description>Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safety and promising early results in patients with heart failure.</description><identifier>ISSN: 1759-5002</identifier><identifier>ISSN: 1759-5010</identifier><identifier>EISSN: 1759-5010</identifier><identifier>DOI: 10.1038/s41569-023-00922-x</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/75/230 ; 692/700/565/1436 ; Cardiac Imaging ; Cardiac Surgery ; Cardiology ; Clinical Outlook ; Diabetes ; Ejection fraction ; Enzymes ; Heart failure ; Hospitalization ; Hyperkalemia ; Kidney diseases ; Medicine ; Medicine &amp; Public Health</subject><ispartof>Nature reviews cardiology, 2023-10, Vol.20 (10), p.645-646</ispartof><rights>Springer Nature Limited 2023</rights><rights>Springer Nature Limited 2023.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-a6a60c6d1d0cca536961ae7a9a4986b054ad34dff4dfab40df57b6c060f4713</citedby><cites>FETCH-LOGICAL-c352t-a6a60c6d1d0cca536961ae7a9a4986b054ad34dff4dfab40df57b6c060f4713</cites><orcidid>0000-0001-8364-3447 ; 0000-0002-5640-0332</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41569-023-00922-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41569-023-00922-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Filippatos, Gerasimos</creatorcontrib><creatorcontrib>Farmakis, Dimitrios</creatorcontrib><title>Non-steroidal mineralocorticoid receptor antagonists in heart failure</title><title>Nature reviews cardiology</title><addtitle>Nat Rev Cardiol</addtitle><description>Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safety and promising early results in patients with heart failure.</description><subject>692/699/75/230</subject><subject>692/700/565/1436</subject><subject>Cardiac Imaging</subject><subject>Cardiac Surgery</subject><subject>Cardiology</subject><subject>Clinical Outlook</subject><subject>Diabetes</subject><subject>Ejection fraction</subject><subject>Enzymes</subject><subject>Heart failure</subject><subject>Hospitalization</subject><subject>Hyperkalemia</subject><subject>Kidney diseases</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><issn>1759-5002</issn><issn>1759-5010</issn><issn>1759-5010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LAzEQhhdRsFb_gKcFL15WJ5-7e5RSP6DoQe9hms3WlG1SkyzUf2-0ouDBw5AhPO_L8BTFOYErAqy5jpwI2VZAWQXQUlrtDooJqUVbCSBw-LMDPS5OYlwDSF4LNinmj95VMZngbYdDubHOBBy89iFZnf_KYLTZJh9KdAlX3tmYYmld-WowpLJHO4zBnBZHPQ7RnH2_0-L5dv4yu68WT3cPs5tFpZmgqUKJErTsSAdao2CylQRNjS3ytpFLEBw7xru-z4NLDl0v6qXUIKHnNWHT4nLfug3-bTQxqY2N2gwDOuPHqGgjmtwjeZPRiz_o2o_B5dsyJTkHmoVkiu4pHXyMwfRqG-wGw7sioD69qr1Xlb2qL69ql0NsH4oZdisTfqv_SX0Av7t8fA</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Filippatos, Gerasimos</creator><creator>Farmakis, Dimitrios</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8364-3447</orcidid><orcidid>https://orcid.org/0000-0002-5640-0332</orcidid></search><sort><creationdate>20231001</creationdate><title>Non-steroidal mineralocorticoid receptor antagonists in heart failure</title><author>Filippatos, Gerasimos ; Farmakis, Dimitrios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-a6a60c6d1d0cca536961ae7a9a4986b054ad34dff4dfab40df57b6c060f4713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>692/699/75/230</topic><topic>692/700/565/1436</topic><topic>Cardiac Imaging</topic><topic>Cardiac Surgery</topic><topic>Cardiology</topic><topic>Clinical Outlook</topic><topic>Diabetes</topic><topic>Ejection fraction</topic><topic>Enzymes</topic><topic>Heart failure</topic><topic>Hospitalization</topic><topic>Hyperkalemia</topic><topic>Kidney diseases</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Filippatos, Gerasimos</creatorcontrib><creatorcontrib>Farmakis, Dimitrios</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Filippatos, Gerasimos</au><au>Farmakis, Dimitrios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-steroidal mineralocorticoid receptor antagonists in heart failure</atitle><jtitle>Nature reviews cardiology</jtitle><stitle>Nat Rev Cardiol</stitle><date>2023-10-01</date><risdate>2023</risdate><volume>20</volume><issue>10</issue><spage>645</spage><epage>646</epage><pages>645-646</pages><issn>1759-5002</issn><issn>1759-5010</issn><eissn>1759-5010</eissn><abstract>Novel non-steroidal mineralocorticoid receptor antagonists (MRAs) have improved pharmacological properties compared with steroidal MRAs. Among the non-steroidal MRAs, finerenone has been approved for patients with chronic kidney disease who have diabetes mellitus and has demonstrated favourable safety and promising early results in patients with heart failure.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/s41569-023-00922-x</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-8364-3447</orcidid><orcidid>https://orcid.org/0000-0002-5640-0332</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1759-5002
ispartof Nature reviews cardiology, 2023-10, Vol.20 (10), p.645-646
issn 1759-5002
1759-5010
1759-5010
language eng
recordid cdi_proquest_miscellaneous_2858986648
source SpringerLink Journals
subjects 692/699/75/230
692/700/565/1436
Cardiac Imaging
Cardiac Surgery
Cardiology
Clinical Outlook
Diabetes
Ejection fraction
Enzymes
Heart failure
Hospitalization
Hyperkalemia
Kidney diseases
Medicine
Medicine & Public Health
title Non-steroidal mineralocorticoid receptor antagonists in heart failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T08%3A12%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-steroidal%20mineralocorticoid%20receptor%20antagonists%20in%20heart%20failure&rft.jtitle=Nature%20reviews%20cardiology&rft.au=Filippatos,%20Gerasimos&rft.date=2023-10-01&rft.volume=20&rft.issue=10&rft.spage=645&rft.epage=646&rft.pages=645-646&rft.issn=1759-5002&rft.eissn=1759-5010&rft_id=info:doi/10.1038/s41569-023-00922-x&rft_dat=%3Cproquest_cross%3E2858986648%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2864402175&rft_id=info:pmid/&rfr_iscdi=true